Certara Divests Regulatory and Medical Writing Business to Veristat for $135 Million to Focus on AI-Driven Drug Development
核心洞察
Certara has entered a definitive agreement to sell its Regulatory and Medical Writing business to Veristat (搜索) for up to $135 million, with the transaction expected to close in Q2 2026.
The divestiture allows Certara to sharpen its focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence solutions, emphasizing AI-integrated modeling and simulation.
The sold business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025, employing approximately 220 staff members.
Certara, Inc. (Nasdaq: CERT) announced on April 22, 2026, that it has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat (搜索) for a consideration of up to $135 million. The transaction represents a strategic move to concentrate resources on the company's core Model-Informed Drug Development (MIDD) and Clinical Intelligence solutions, with an emphasis on AI-integrated modeling and simulation technologies.
Strategic Focus on AI-Driven Drug Development
"Certara's strategy is centered on expanding the scale, reach, and impact of our MIDD and Clinical Intelligence solutions," said Jon Resnick, Chief Executive Officer. "This transaction underlines our commitment to the acceleration of AI-integrated modeling and simulation across the drug development lifecycle."
The divestiture aligns with Certara's broader strategy to enhance its position as a leader in biosimulation software and technology. The company serves more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries, using its platforms to transform traditional drug discovery and development processes.
Financial Performance and Transaction Details
The Regulatory and Medical Writing business demonstrated solid financial performance in 2025, generating $50 million in revenue and $17 million in adjusted EBITDA, excluding unallocated overhead expense. The business unit includes approximately 220 employees who will transition to Veristat (搜索) as part of the transaction.
The transaction is expected to close during the second quarter of 2026, subject to customary closing conditions. Certara plans to update its 2026 guidance to reflect the impact of the business sale upon transaction completion.
Investment in Core Capabilities
"This transaction enhances our ability to accelerate investment in Certara's integrated MIDD platform for customers, while sharpening our focus on product innovation and operational excellence," Resnick explained. "Consistent with our strategy, we intend to deploy the proceeds to drive long-term value for customers, patients, and shareholders."
The proceeds from the sale will be strategically deployed to strengthen Certara's core biosimulation capabilities and expand its AI-integrated modeling solutions. This focus on MIDD and Clinical Intelligence positions the company to better serve the evolving needs of the pharmaceutical industry as it increasingly adopts model-informed approaches to drug development.
Advisory Teams
Perella Weinberg Partners LP (搜索) served as the financial advisor, and Troutman Pepper Locke LLP (搜索) served as legal counsel to Certara. Guggenheim Securities, LLC (搜索) served as the financial advisor, and McDermott Will & Schulte (搜索) served as legal counsel to Veristat (搜索) in the transaction.